JAK2 and breast carcinoma: Our data showed that azilsartan treatment reduced the expression of NF-kB mRNA, which is involved in many cellular pathways in malignant tumors, and decreased the expression of IL-6, JAK2 and STAT3 proteins, which promote the proliferation, metastasis, invasion and angiogenesis in breast cancers, resulting in the suppression of this NF-kB/IL-6/JAK2/STAT3 signaling pathway.